Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Brian Elliott, MD
Novartis Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Novartis Investigative Site
Toronto, Ontario, Canada
- University of California San Diego Moores Cancer Center
La Jolla, California, United States
- University of California at Los Angeles Oncology
Los Angeles, California, United States
- Scri- Colorado Blood Cancer Institute
Denver, Colorado, United States
- H Lee Moffitt Cancer Center and Research Institute Oncology
Tampa, Florida, United States
- Northside Hospital
Atlanta, Georgia, United States
- University of Chicago Medical Center
Chicago, Illinois, United States
- Karmanos Cancer Institute Karmanos - Wayne State
Detroit, Michigan, United States
- Mayo Clinic - Rochester
Rochester, Minnesota, United States
- Washington University School of Medicine-Siteman Cancer Ctr Washington U School of Med
St Louis, Missouri, United States
- Hackensack University Medical Center Hackensack Univ Med Ctr (32)
Hackensack, New Jersey, United States
- University of North Carolina at Chapel Hill University of North Carolina 6
Chapel Hill, North Carolina, United States
- University Hospitals Case Medical Center
Cleveland, Ohio, United States
- Oregon Health Sciences University
Portland, Oregon, United States
- Tennessee Oncology Sarah Cannon Research Inst.
Nashville, Tennessee, United States
- Vanderbilt Univeristy Oncology
Nashville, Tennessee, United States
- Baylor Health Care System/sammons Cancer Center Oncology
Dallas, Texas, United States
- Texas Transplant Physicians Group Oncology 2
San Antonio, Texas, United States
- Fred Hutchinson Cancer Research Center Oncology
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 6 Feb 2014
- Primary completion
- 30 Apr 2018
- Completion
- 30 Apr 2018
- Last update posted
- 17 Mar 2021
- Registered enrollment
- 60
- Registry id
- NCT01883362
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.